• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconOzempic

Ozempic

Page 5 of 9
Exclusive: The COO of Hims & Hers was the third person to try their new weight loss drugs—and she’s ready to share her story
Health
Exclusive: The COO of Hims & Hers was the third person to try their new weight loss drugs—and she’s ready to share her story
By Alexa MikhailAugust 14, 2024
Here’s the real reason Ozempic-like weight-loss drugs are so popular
Commentary
Here’s the real reason Ozempic-like weight-loss drugs are so popular
By Bill NovelliAugust 12, 2024
An Ozempic (semaglutide) injection pen is seen on a kitchen table.
Health
How Denmark got homegrown giant Novo Nordisk to lower Ozempic prices
By Arthur Allen and KFF Health NewsAugust 7, 2024
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
Magazine
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
By Erika FryAugust 2, 2024
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary
I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad
By Angela FitchJuly 30, 2024
Thomas Schinecker, CEO of Roche Holding.
Retail
An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value
By Naomi Kresge, Lisa Pham and BloombergJuly 23, 2024
Obesity medicine physician Dr. Nisha Patel breaks down five weight loss myths that “need to die” with Fortune.
Health
The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor
By Lindsey LeakeJuly 18, 2024
A bathroom scale is surrounded by colorful pills.
Health
Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By Damian Garde and BloombergJuly 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features
Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By Jessica Mathews and Alena BotrosJuly 9, 2024
Close-up of an Ozempic pen in a greenwash style
Health
Ozempic linked to rare cases of vision loss in Harvard study
By Robert Langreth and BloombergJuly 3, 2024
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
Health
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk.
Health
A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails
By Naomi Kresge and BloombergJune 27, 2024
EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
Health
EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
By Naomi Kresge and BloombergJune 26, 2024
Danone and Nestle search for a way around Ozempic Revolution with high protein yogurt and vitamins against hair-loss
Health
Danone and Nestle search for a way around Ozempic Revolution with high protein yogurt and vitamins against hair-loss
By Dasha Afanasieva, Deena Shanker and BloombergJune 24, 2024
A photo of the packet for anti-obesity drug Wegovy.
Tech
India’s gray market is selling Wegovy at less than 10% of U.S. prices—even though weight-loss drugs aren’t officially available in the country
By Satviki Sanjay and BloombergJune 19, 2024
1...
  • 3
  • 4
  • 5
  • 6
  • 7
...9
Most Popular
Success
Mark Cuban says he has the solution to growing income inequality, and it's to reward every employee—from CEO to janitor—with company stockplaceholder alt text
By Sasha RogelbergJuly 20, 2026
Success
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billionplaceholder alt text
By Sydney LakeJuly 20, 2026
AI
'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimisticplaceholder alt text
By Jason MaJuly 18, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.